Organs-on-chips Market by Type (Brain-on-a-chip, Heart-on-a-chip, Kidney-on-a-chip), Application (Drug Discovery, Physiological Model Development, Toxicology Research), End-user - Global Forecast 2024-2030

[194 Pages Report] The Organs-on-chips Market size was estimated at USD 119.50 million in 2023 and expected to reach USD 157.36 million in 2024, at a CAGR 33.92% to reach USD 923.59 million by 2030.

Organs-on-chips are microfluidic devices that simulate the physiological responses of organ systems in an in vitro setting. Organs-on-chips are composed of a transparent, flexible polymer; these chips contain microchannels lined with living cells and tissue that mimic the structure and function of full-sized organs. By replicating the biological and mechanical environment of human organs, these devices offer a sophisticated platform for disease modeling, drug testing, and personalized medicine while reducing the need for animal testing. The pressing need for more predictive and accurate models for drug discovery and safety testing boosts the importance of organs-on-chips models. Additionally, regulatory shifts towards reducing animal testing bolster the adoption of organs-on-chips models. However, the integration of organs-on-chips into mainstream research and industry impacts its adoption. Furthermore, technological advancements in microfluidics and 3D cell culture create substantial opportunities for organ-on-chips adoption.

The brain-on-a-chip is a sophisticated device that mimics the neural circuits of the human brain, enabling researchers to study brain physiology and pathology in a controlled environment. Such chips are critical for advancing the understanding of neurological diseases, drug screening, and neurotoxicity testing. Heart-on-a-chip devices replicate the mechanical and electrophysiological properties of the human heart tissue. They are vital for cardiovascular disease research, drug discovery, and toxicity testing. The need for heart-on-chip models is driven by the high prevalence of heart diseases globally and the necessity to develop more targeted and effective treatments. Kidney-on-a-chip models simulate the key functions of human kidney cells, making them crucial for studying kidney diseases, drug metabolism, and nephrotoxicity. The demand for these chips arises from the significant number of patients suffering from renal conditions and the need for better models to facilitate drug development. Lung-on-a-chip models mimic the lung’s respiratory functions, including air and blood flow, making them essential for researching respiratory diseases, evaluating inhalable drug efficacy, and studying toxin exposure effects. The COVID-19 pandemic has further emphasized the need for lung-on-chip models for virus research and drug testing. Skin-on-a-chip devices recreate the complex structure and functions of human skin, offering innovative platforms for dermatological research, cosmetic testing, and drug delivery studies. These chips are increasingly preferred over animal testing for ethical reasons and due to their ability to better mimic human skin responses.

Drug discovery represents a critical application area for organs-on-chips technology, providing a dynamic platform for the screening and evaluation of pharmacological properties of new compounds. The application significantly reduces the dependency on animal models, offering a more human-relevant environment to predict human responses. Physiological model development using organs-on-chips technology provides unprecedented opportunities for understanding complex human diseases, including those that cannot be modeled in animals. This application facilitates the study of disease mechanisms, drug interactions, and the development of personalized medicine. Toxicology research is another significant area where organ-on-chips technology is making remarkable strides. By closely replicating human organ responses, these chips provide a more accurate and relevant means of assessing the toxicity of new compounds, chemicals, and environmental pollutants.

The American region, including the United States & Canada, is at the forefront of the organs-on-chips market, driven by strong research institutions, substantial investments, and supportive government initiatives. Customer needs in the American region focus on drug development efficiency and personalized medicine applications. The European Union has been a supportive environment for organs-on-chips technology, facilitated by funding initiatives. The focus in the European Union is on enhancing drug discovery and safety testing, reducing animal testing, and improving patient outcomes. There is a strong emphasis on regulatory considerations and ethical standards. The Middle East, though nascent in the organs-on-chips market, shows potential for growth. Investments in healthcare infrastructure and a burgeoning interest in advanced technologies suggest expanding opportunities, especially in academic and research institutions. In the APAC region, China, Japan & India are rapidly emerging as key regions in the organs-on-chips market, with significant investments in research and development. The government and private sector's emphasis on healthcare innovation has fueled the expansion of organ-on-chips technology, focusing on drug development and disease models.

The FPNV Positioning Matrix is pivotal in evaluating the Organs-on-chips Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Organs-on-chips Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• German organ-on-chip specialist Dynamic42 raises Series A financing round to expand internationally

  Dynamic42 GmbH, a German innovator specializing in organ-on-chip technology, has successfully secured a mid-seven-figure investment in a Series A funding round. Dynamic42 has consistently demonstrated the societal and economic benefits of its technology, including safer drugs, cost-effective drug development, and a viable alternative to animal testing. [Published On: 2023-06-14]

• Over Euro 3 Million for Organ-On-Chip Development

  The Dutch Research Council (NWO) has reported a significant investment of approximately 22.7 million euros in seven groundbreaking projects aimed at enhancing scientific infrastructure. This includes an allocation of over 3 million euros to the University of Twente for the creation of the innovative Organ-on-Chip Development Centre. Organs-on-chips, which simulate miniaturized versions of human organs, serve as pivotal tools for evaluating the safety and efficacy of various substances, including food components and pharmaceuticals. [Published On: 2023-05-09]

• FDA expands organ-on-a-chip research collaboration

  The US Food and Drug Administration (FDA) has augmented its collaborative efforts with CN Bio, a pioneer in the field of multi-organ microphysiological systems (MPS). This collaboration is focused on harnessing the innovative capabilities of the PhysioMimix Multi-organ System to refine the preclinical assessment of human drug bioavailability. This marks a significant step away from traditional animal model dependencies, which have been identified as inadequate due to physiological and metabolic discrepancies when predicting human responses. [Published On: 2023-01-18]

The report delves into recent significant developments in the Organs-on-chips Market, highlighting leading vendors and their innovative profiles. These include 4DCell, AlveoliX AG, AxoSim, Inc., Beonchip S. L., Bi/ond Solutions B.V., BICO Group AB, BiomimX S.r.l., Cherry Biotech, CN Bio Innovations Limited, Curi Bio, Inc., Dynamic42 GmbH, Elveflow, Emulate, Inc., Emulate, Inc. by UAMS, InSphero AG, Kirkstall Ltd., Micronit B.V., Mimetas B.V., NETRI SAS, Nortis Inc., SynVivo, Inc., The Charles Stark Draper Laboratory, Inc., TissUse GmbH, uFluidix, and Valo Health, Inc..

This research report categorizes the Organs-on-chips Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Brain-on-a-chip
  • Heart-on-a-chip
  • Kidney-on-a-chip
  • Lung-on-a-chip
  • Skin-on-a-chip
• Application
  • Drug Discovery
  • Physiological Model Development
  • Toxicology Research
• End-user
  • Academic & Research Institutes
  • Cosmetics Industry
  • Pharmaceutical & Biotechnology Companies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

1. What is the market size and forecast of the Organs-on-chips Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Organs-on-chips Market?
3. What are the technology trends and regulatory frameworks in the Organs-on-chips Market?
4. What is the market share of the leading vendors in the Organs-on-chips Market?
5. Which modes and strategic moves are suitable for entering the Organs-on-chips Market?